Analysis of exhaled breath condensate (EBC) is a noninvasive method for studying the composition of airway lining fluid and has the potential for assessing lung inflammation. EBC is mainly formed by water vapor, but also contains aerosol particles in which several biomolecules including leukotrienes, 8-isoprostane, prostaglandins, hydrogen peroxide, nitric oxide-derived products, and hydrogen ions, have been detected in healthy subjects. Inflammatory mediators in EBC are detected in healthy subjects and some of them are elevated in patients with different lung diseases. Analysis of EBC is completely noninvasive, is particularly suitable for longitudinal studies, and is potentially useful for assessing the response to pharmacological therapy. Identification of selective profiles of biomarkers of lung diseases might also have a diagnostic value. However, EBC analysis currently has important limitations. The lack of standardized procedures for EBC analysis and validation of some analytical techniques makes it difficult comparison of results from different laboratories. Analysis of EBC is currently more useful for relative measures than for quantitative assessment of inflammatory mediators. Reference analytical techniques are required to provide definitive evidence for the presence of some inflammatory mediators in EBC and for their accurate quantitative assessment in this biological fluid. Several methodological issues need to be addressed before EBC analysis can be considered for clinical applications. However, further research in this area is warranted due to the relative lack of noninvasive methods for assessing lung inflammation.
Adelroth, E. (1998) How to measure airway inflammation: bronchoalveolar lavage and airway biopsies. Can Respir J5: 18A—21A.
2.
Anonymous (1999) Recommendations for standardised procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children — 1999. Official statement of the American Thoracic Society 1999. Am J Respir Crit Care Med160: 2104—2117.
3.
Anonymous (2005). ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med171: 912—930.
4.
Antczak, A. et al. (1997) Increased hydrogen peroxide and thiobarbituric acid-reactive products in expired breath condensate of asthmatic patients . Eur Respir J10: 1235—1241.
5.
Antczak, A. et al. (2001) Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med166: 301—306.
6.
Balint, B. et al. (2001) Increased nitrotyrosine
7.
in exhaled breath condensate in cystic fibrosis. Eur Respir J17: 1201—1207.
8.
Baraldi, E. et al. (2003a) Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations. Thorax58: 505—509.
9.
Baraldi, E. et al. (2003b) Increased exhaled 8-isoprostane in childhood asthma. Chest124: 25—31.
10.
Baraldi, E. et al. (2006) 3-Nitrotyrosine, a marker of nitrosative stress, is increased in breath condensate of allergic asthmatic children. Allergy61: 90—96.
Berlyne, G.S. et al.(2000) A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation. J Allergy Clin Immunol106: 638—644.
13.
Biernacki, W.A. et al. (2003) Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax58: 294—298.
14.
Bodini, A. et al. (2006) Flunisolide decreases exhaled nitric oxide and nitrotyrosine levels in asthmatic children. Mediators Inflamm4: 31919.
15.
Brunetti, L. et al. (2006) Exhaled breath condensate pH measurement in children with asthma, allergic rhinitis and atopic dermatitis. Pediatr Allergy Immunol17: 422—427.
16.
Cap, P. et al. (2004) Gas-chromatography mass spectrometry analysis of exhaled leukotrienes in asthmatic patients. Thorax59: 465—470.
17.
Carpagnano, G.E. et al. (2003a) 8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy . Chest124: 1386—1392.
18.
Carpagnano, G.E. et al. (2003b) Increased leukotriene B4 and interleukin-6 in exhaled breath condensate in cystic fibrosis. Am J Respir Crit Care Med167: 1109—1112.
19.
Carpagnano, G.E. et al. (2005) 3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer. Am J Respir Crit Care Med172: 738—744.
20.
Carpenter, C.T. et al. (1998) Exhaled breath condensate isoprostanes are elevated in patients with acute lung injury and ARDS. Chest114: 1653—1659.
21.
Carraro, S. et al. (2005) Exhaled breath condensate cysteinyl leukotrienes are increased in children with exercise-induced bronchoconstriction. J Allergy Clin Immunol115: 764—770.
22.
Celio, S. et al. (2006) Free 3-nitrotyrosine in exhaled breath condensates of children fails as a marker for oxidative stress in stable cystic fibrosis and asthma. Nitric Oxide15: 226—232.
23.
Cepelak, I. et al. (2007) Exhaled breath condensate: a new method for lung disease diagnosis. Clin Chem Lab Med (in press).
24.
Corradi, M. et al. (2001) Increased nitrosothiols in exhaled breath condensate in inflammatory airway diseases. Am J Respir Crit Care Med163: 854—858.
25.
Corradi, M. et al. (2003a) Aldehydes and glutathione in exhaled breath condensate of children with asthma exacerbations. Am J Respir Crit Care Med167: 395—399.
26.
Corradi, M. et al. (2003b) Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med167: 1380—1386.
27.
Csoma, Z. et al. (2002) Increased leukotrienes in exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med166: 1345—1349.
28.
Cunningham, S. et al. (2000) Measurement of inflammatory markers in the breath condensate of children with asthma. Eur Respir J15: 955—957.
29.
De Benedetto, F. et al. (2001) Validation of a new technique to assess exhaled hydrogen peroxide: results from normals and COPD patients. Monaldi Arch Chest Dis55: 185—188.
30.
Decramer, M. et al. (2005) Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet365: 1552—1560.
31.
Dekhuijzen, R.P.N. et al. (1996) Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease . Am J Respir Crit Care Med154: 813—816.
32.
Dohlman, A.W. et al. (1993) Expired breath hydrogen peroxide is a marker of acute airway inflammation in pediatric patients with asthma. Am Rev Resp Dis148: 955—960.
33.
Dupont, L.J. et al. (2006) The pH of exhaled breath condensate of patients with allograft rejection after lung transplantation. Am J Transplant6: 1486—1492.
34.
Dwyer, T.M. (2001) Expired breath condensate (EBC) and the ultimate disposition of airway surface liquid (ASL). Am J Respir Crit Care Med163: A406.
35.
Effros, R.M. et al. (2002) Dilution of respiratory solutes in exhaled condensates. Am J Respir Crit Care Med165: 663—669.
36.
Effros, R.M. et al. (2003) A simple method for estimating respiratory solute dilution in exhaled breath condensates. Am J Respir Crit Care Med168: 1500—1505.
37.
Effros, R.M. et al. (2005a) Utility of exhaled breath condensates in chronic obstructive pulmonary disease: a critical review. Curr Opin Pulm Med11: 135—139.
38.
Effros, R.M. et al. (2005b) Exhaled breath condensate: formation and physicochemical properties. In Montuschi P (ed), New perspectives in monitoring lung inflammation: analysis of exhaled breath condensate. CRC Press: Boca Raton, Florida, pp. 31—52.
39.
Emelyanov, A. et al. (2001) Elevated concentrations of exhaled hydrogen peroxide in asthmatic patients. Chest120: 1136—1139.
40.
Ferreira, I.M. et al. (2001) Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: effects of inhaled beclomethasone. Am J Respir Crit Care Med164: 1012—1015.
41.
Fixman, E.D. et al. (2007) Basic mechanisms of development of airway structural changes in asthma. Eur Respir J29: 379—389.
42.
Gaber, F. et al. (2006) Saliva is one likely source of leukotriene B4 in exhaled breath condensate. Eur Respir J28: 1229—1235.
43.
Gajdocsi, R. et al. (2003) The reproducibility and accuracy of the on-line hydrogen peroxide bioassay and the decreasing effect of storage on H2O2 concentration. Eur Respir J22, Suppl. 45: 279s.
44.
Ganas, K. et al. (2001) Total nitrite/nitrate in expired breath condensate of patients with asthma. Respir Med95: 649—654.
45.
Gaston, B. et al. (1998) Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure. Lancet351: 1317—1319.
46.
Gessner, C. et al. (2004) Detection of p53 gene mutations in exhaled breath condensate of non-small cell lung cancer patients. Lung Cancer43: 215—222.
47.
Gianazza, E. et al. (2003) Increased keratin content detected by proteomic analysis of exhaled breath condensate from healthy persons who smoke. Am J Med117: 51—54.
48.
Goen, T. et al. (2005) Sensitive and accurate analyses of free 3-nitrotyrosine in exhaled breath condensate by LC-MS/MS. Chromatogr B Analyt Technol BiomedLife Sci826: 261—266.
49.
Hanazawa, T. et al. (2000) Increased nitrotyrosine in exhaled breath condensate of patients with asthma. Am J Respir Crit Care Med162: 1273—1276.
50.
Horvath, I. et al. (1998) Combined use of exhaled hydrogen peroxide and nitric oxide in monitoring asthma. Am J Respir Crit Care Med158: 1042—1046.
51.
Horvath, I. et al. (2005) Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J26: 523—548.
52.
Hunt, J. (2002) Exhaled breath condensate: an evolving tool for non-invasive evaluation of lung disease. J Allergy Clin Immunol110: 28—34.
53.
Hunt, J. et al. (1995) Condensed expirate nitrite as a home marker for acute asthma. Lancet346: 1235—1236.
54.
Hunt, J.F. et al. (2000) Endogenous airway acidification. Implications for asthma pathophysiology. Am J Respir Crit Care Med161: 694—699.
55.
Huszar, E. et al. (2005) Comparative measurement of thromboxane A2 metabolites in exhaled breath condensate by different immunoassays. Inflamm Res54: 350—355.
56.
Jackson, A.S. et al. (2007) Comparison of biomarkers in exhaled breath condensate and bronchoalveolar lavage. Am J Respir Crit Care Med175: 222—227.
57.
Jobsis, Q. et al. (2000) Hydrogen peroxide and nitric oxide in exhaled air of children with cystic fibrosis during antibiotic treatment. Eur Respir J16: 95—100.
58.
Jobsis, Q. et al. (1997) Hydrogen peroxide in exhaled air is increased in stable asthmatic children. Eur Respir J10: 519—521.
59.
Kasielski, M. and Nowak, D. (2001) Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med95: 448—456.
60.
Kharitonov, S.A. and Barnes, P.J. (2006) Exhaled biomarkers. Chest130: 1541—1546.
61.
Kharitonov, S.A. and Barnes, P.J. (2001) Exhaled markers of pulmonary disease. Am J Respir Crit Care Med163: 1693—1722.
62.
Kharitonov, S.A. et al. (2002) Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma . Thorax57: 889—896.
63.
Kietzmann, D. et al. (1993) Hydrogen peroxide in expired breath condensate of patients with acute respiratory failure and with ARDS. Intensive Care Med19: 78—81.
64.
Kostikas, K. et al. (2002) pH in expired breath condensate of patients with inflammatory airway diseases. Am J Respir Crit Care Med165: 1364—1370.
65.
Kostikas, K. et al. (2003) Oxidative stress in expired breath condensate of patients with COPD. Chest124: 1373—1380.
66.
Kostikas, K. et al. (2005) Leukotriene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma. Chest127: 1553—1559.
67.
Kullmann, T. et al. (2006) Exhaled breath condensate pH standardised for CO2 partial pressure. Eur Respir J29: 496—501.
68.
Kwiatkowska, S. et al. (2007) Elevated exhalation of hydrogen peroxide and circulating IL-18 in patients with pulmonary tuberculosis. Respir Med101: 574—580.
69.
Larstad, M. et al. (2002) Determination of malondialdehyde in breath condensate by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol BiomedLife Sci766: 107—114.
70.
Larstad, M. et al. (2003) Influence of sampling time on malondialdehyde levels and pH in exhaled breath condensate. Eur Respir J, Suppl 45: 38s.
71.
Larstad, M. et al. (2005) Selective quantification of free 3-nitrotyrosine in exhaled breath condensate in asthma using gas chromatography/tandem mass spectrometry. Nitric Oxide13: 134—144.
72.
Loukides, S. et al. (1998) Elevated levels of expired breath hydrogen peroxide in bronchiectasis. Am J Respir Crit Care Med158: 991—994.
73.
Matsunaga, K. et al. (2006) Airway cytokine expression measured by means of protein array in exhaled breath condensate: correlation with physiologic properties in asthmatic patients. J Allergy Clin Immunol118: 84—90.
74.
McCafferty, J.B. et al. (2004) Effects of breathing pattern and inspired air conditions on breath condensate volume, pH, nitrite, and protein concentrations . Thorax59: 694—698.
75.
McKinney, E.T. et al. (2000) Plasma, urinary, and salivary 8-epi-prostaglandin F2α levels in normotensive and preeclamptic pregnancies. Am J Obstet Gynecol183: 874—877.
76.
Mondino, C. et al. (2004) Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. J Allergy Clin Immunol114: 761—767.
77.
Montuschi, P. (2002) Indirect monitoring of lung inflammation. Nat Rev Drug Discov1: 238—242.
78.
Montuschi, P. (editor) (2005a) New perspectives in monitoring lung inflammation: analysis of exhaled breath condensate. CRC Press: Boca Raton, Florida.
79.
Montuschi, P. et al. (2005b) Analysis of exhaled breath condensate: methodological issues. In Montuschi P (ed), New perspectives in monitoring lung inflammation: analysis of exhaled breath condensate. CRC Press: Boca Raton, Florida, pp. 11—30.
80.
Montuschi, P. and Barnes, P.J. (2002a) Analysis of exhaled breath condensate for monitoring airway inflammation. Trends Pharmacol Sci23: 232—237.
81.
Montuschi, P. and Barnes, P.J. (2002b) Exhaled leukotrienes and prostaglandins in asthma . J Allergy Clin Immunol109: 615—620.
82.
Montuschi, P. et al. (1999) Increased 8-isoprostane, a biomarker of oxidative stress, in exhaled condensate of asthma patients . Am J Respir Crit Care Med160: 216—220.
83.
Montuschi, P. et al. (2000) Exhaled 8-isoprostane as an in vivo biomarker of oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med162: 1175—1177.
84.
Montuschi, P. et al. (2002) Ozone-induced increase in exhaled 8-isoprostane in healthy subjects is resistant to inhaled budesonide. Free Radic Biol Med33: 1403—1408.
85.
Montuschi, P. et al. (2003a) Methodological aspects of exhaled prostanoid measurements. Eur Respir J, Suppl. 45: 18s.
86.
Montuschi, P. et al. (2003b) Validation of 8-isoprostane and prostaglandin E2 measurements in exhaled breath condensate. Inflamm Res52: 502—507.
87.
Montuschi, P. et al. (2003c) Validation of leukotriene B4 measurements in exhaled breath condensate. Inflamm Res52: 69—73.
88.
Montuschi, P. et al. (2003d) Exhaled leukotrienes and prostaglandins in COPD. Thorax58: 585—588. Chest127: 1553—1559.
89.
Montuschi, P. et al. (2004a) Ion trap liquid chromatography/tandem mass spectrometry analysis of leukotriene B4 in exhaled breath condensate. Rapid Commun Mass Spectrom18: 2723—2729.
90.
Montuschi, P. et al. (2004b) Isoprostanes: markers and mediators of oxidative stress. FASEB J18: 1791—1800.
91.
Montuschi, P. et al. (2005a) Liquid chromatography/mass spectrometry analysis of exhaled leukotriene B4 in asthmatic children. Respir Res19: 6:119.
92.
Montuschi, P. et al. (2005b) Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax60: 827—833.
93.
Montuschi, P. et al. (2006) Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. J Allergy Clin Immunol118: 347—353.
94.
Montuschi, P. et al. (2007) Insights into oxidative stress: the isoprostanes . Curr Med Chem14: 703—717.
95.
Morrow, J.D. et al. (1990) A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA87: 9383—9387.
96.
Mutlu, G.M. et al. (2001) Collection and analysis of exhaled breath condensate in humans. Am J Respir Crit Care Med164: 731—737.
97.
Nicolau, N.C. et al. (2006) Exhaled breath condensate pH and childhood asthma: unselected birth cohort study. Am J Respir Crit Care Med174: 254—259.
98.
Nowak, D. et al. (1999) Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking. Respir Med93: 389—396.
99.
O'Donnell, R. et al. (2006) Inflammatory cells in the airways in COPD . Thorax61: 448—454.
100.
Paget-Brown, A.O. et al. (2006) Normative data for pH of exhaled breath condensate. Chest129: 426—430.
101.
Prieto, L. et al. (2007) Differences in exhaled breath condensate pH measurements between samples obtained with two commercial devices. Respir Med (in press).
102.
Profita, M. et al. (2006) Noninvasive methods for the detection of upper and lower airway inflammation in atopic children. J Allergy Clin Immunol118: 1068—1074.
103.
Ratnawati, R. et al. (2006) Exhaled breath condensate nitrite/nitrate and pH in relation to pediatric asthma control and exhaled nitric oxide. Pediatr Pulmonol41: 929—936.
104.
Rickmann, J. et al. (2001) Breath condensate reflects different compartments of respiratory tract depending on ventilation pattern. Am J Respir Crit Care Med163: A407.
105.
Robroeks, C.M. et al. (2006) Cytokines in exhaled breath condensate of children with asthma and cystic fibrosis. Ann Allergy Asthma Immunol96: 349—355.
106.
Rosias, P.P.R. et al. (2006) Breath condenser coatings affect measurement of biomarkers in exhaled breath condensate. Eur Respir J28: 1036—1041.
107.
Rozy, A. et al. (2006) Inflammatory markers in the exhaled breath condensate of patients with pulmonary sarcoidosis. J Physiol Pharmacol57 (Suppl 4): 335—340.
108.
Rysz, J. et al. (2007) Increased hydrogen peroxide concentration in the exhaled breath condensate of stable COPD patients after nebulized N-acetylcysteine . Pulm Pharmacol Ther20: 281—289.
109.
Sabroe, I. et al. (2007) Targeting the networks that underpin contiguous immunity in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med175: 306—311.
110.
Sack, U. et al. (2006) Multiplex analysis of cytokines in exhaled breath condensate. Cytometry A 69: 169—172.
111.
Sandrini, A. et al. (2003a) Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma. Chest124: 1334—1340.
112.
Sandrini, A. et al. (2003b) Effect of nasal triamcinolone acetonide on lower airway inflammatory markers in patients with allergic rhinitis. J Allergy Clin Immunol111: 313—320.
113.
Scheideler, L. et al. (1993) Detection of nonvolatile macromolecules in breath: a possible diagnostic tool?Am Rev Respir Dis148: 778—784.
114.
Schleiss, M.B. et al. (2000) The concentration of hydrogen peroxidein exhaled air depends on expiratory floe rate. Eur Respir J16: 1115—1118.
115.
Shahid, S.K. et al. (2002) Increased interleukin-4 and decreased interferon-gamma in exhaled breath condensate of children with asthma. Am J Respir Crit Care Med165: 1290—1293.
116.
Shahid, S.K. et al. (2005) Exhaled 8-isoprostane in childhood asthma . Respir Res6: 79.
117.
Shibata, A. et al. (2006) Increased leukotriene E4 in the exhaled breath condensate of children with mild asthma. Chest130: 1718—1722.
118.
Shimizu, Y. et al. (2007) Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease. Respiration (in press).
119.
Smith, A.D. et al. (2005) Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med352: 2163—2173.
120.
Soyer, O.U. et al. (2006) Comparison of two methods for exhaled breath condensate collection. Allergy61: 1016—1018.
121.
Svensson, S. et al. (2003) Sampling time is important for the collection of hydrogen peroxide in exhaled breath condensate (EBC). Eur Respir J, Suppl 45: 78s.
122.
van Beurden, W.J. et al.(2003a) Effects of inhaled corticosteroids with different lung deposition on exhaled hydrogen peroxide in stable COPD patients . Respiration70: 242—248.
123.
van Beurden, W.J. et al. (2003b) Markers of inflammation and oxidative stress during lower respiratory tract infections in COPD patients. Monaldi Arch Chest Dis59: 273—280.
124.
Vass, G. et al. (2003) Comparison of nasal and oral inhalation during exhaled breath condensate collection. Am J Respir Crit Care Med167: 850—855.
125.
Vaughan, J. et al. (2003) Exhaled breath condensate pH is a robust and reproducible assay of airway acidity. Eur Respir J22: 889—894.
126.
Vogelberg, C. et al. (2003) Pseudomonas aeruginosa and Burkholderia cepacia cannot be detected by PCR in the breath condensate of patients with cystic fibrosis. Pediatr Pulmonol36: 348—352.
127.
Walsh, B.K. et al. (2006) Exhaled-breath condensate pH can be safely and continuously monitored in mechanically ventilated patients. Respir Care51: 1125—1131.
128.
Wenzel, S.E. (2006) Asthma: defining of the persistent adult phenotypes . Lancet368: 804—813.
129.
Zakrzewski, J.T. et al. (1987) Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. Am Rev Respir Dis136: 779—782.
130.
Zanconato, S. et al. (2004) Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma. J Allergy Clin Immunol113: 257—263.
131.
Zappacosta, B. et al. (2001) A fast chemiluminescent method for H(2)O(2) measurement in exhaled breath condensate. Clin Chim Acta310: 187—191.
